Abstract
Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Current Pharmaceutical Design
Title: The Ultra High Risk Approach to Define Psychosis Risk
Volume: 18 Issue: 4
Author(s): Alison R. Yung, Paolo Fusar-Poli and Barnaby Nelson
Affiliation:
Keywords: Psychosis, schizophrenia, prodrome, At Risk Mental State, Ultra High Risk (UHR), Clinical High Risk, subthreshold, depression, mania, Risk Syndrome
Abstract: Although prodromal symptoms of psychosis have long been recognized, the clinical management of psychotic disorders conventionally begins at the first episode of frank psychosis, and, until recently, the period immediately preceding the first episode received relatively little attention. Over the last fifteen years, there has been increasing academic and clinical interest in people presenting with potentially prodromal symptoms. This clinical syndrome has been termed an “At Risk Mental State”, and operationalised criteria, the “Ultra High Risk (UHR)”, or “Clinical High Risk” criteria, have been developed to identify the syndrome. We will review here the mainstreams of the UHR paradigms focusing on the conceptual basis, potentials and limtations in current psychiatric research.
Export Options
About this article
Cite this article as:
R. Yung Alison, Fusar-Poli Paolo and Nelson Barnaby, The Ultra High Risk Approach to Define Psychosis Risk, Current Pharmaceutical Design 2012; 18 (4) . https://dx.doi.org/10.2174/138161212799316299
DOI https://dx.doi.org/10.2174/138161212799316299 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Aβ(1-42)Oligomerization, Fibrillization and Acetylcholinesterase Activity by Some Anti-Inflammatory Drugs: An in vitro Study
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets Significant Overlapping Modules and Biological Processes Between Stroke and Coronary Heart Disease
CNS & Neurological Disorders - Drug Targets Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Structural Neuroimaging Findings in Major Depressive Disorder Throughout Aging: A Critical Systematic Review of Prospective Studies
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Cardiovascular Drug Discovery Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry Differences Between Parkinson’s and Huntington’s Diseases and Their Role for Prioritization of Stem Cell-Based Treatments
Current Molecular Medicine Role of CNS Transporters in the Pharmacotherapy of HIV-1 Associated Neurological Disorders
Current Pharmaceutical Design VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina
Current Alzheimer Research Patient Involvement and Shared Decision-Making in Mental Health Care
Current Clinical Pharmacology The Effects of IGF-1 on Trk Expressing DRG Neurons with HIV-gp120- Induced Neurotoxicity
Current HIV Research DHA–lysophospholipid Production
Current Organic Chemistry Preface
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Central Nervous System-Related
Current Bioactive Compounds